Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · June 18, 2024

Effects of Gantenerumab or Solanezumab on Downstream Biomarkers in Patients With Dominantly Inherited Alzheimer's Disease

JAMA Neurology


Additional Info

JAMA Neurology
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
JAMA Neurol 2024 Jun 01;81(6)582-593, O Wagemann, H Liu, G Wang, X Shi, T Bittner, MA Scelsi, MR Farlow, DB Clifford, C Supnet-Bell, AM Santacruz, AJ Aschenbrenner, JJ Hassenstab, TLS Benzinger, BA Gordon, KA Coalier, C Cruchaga, L Ibanez, RJ Perrin, C Xiong, Y Li, JC Morris, JJ Lah, SB Berman, ED Roberson, CH van Dyck, D Galasko, S Gauthier, GR Hsiung, WS Brooks, J Pariente, CJ Mummery, GS Day, JM Ringman, PC Mendez, P St George-Hyslop, NC Fox, K Suzuki, HR Okhravi, J Chhatwal, J Levin, M Jucker, JR Sims, KC Holdridge, NK Proctor, R Yaari, SW Andersen, M Mancini, J Llibre-Guerra, RJ Bateman, E McDade

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading